LAMATTINA JOHN L 4
4 · LIGAND PHARMACEUTICALS INC · Filed Jun 12, 2026
Research Summary
AI-generated summary of this filing
Ligand (LGND) Director John L. LaMattina Sells Shares
What Happened
- John L. LaMattina, a director of Ligand Pharmaceuticals, sold a total of 4,591 shares in open-market transactions on June 10, 2026, generating approximately $1,151,774 in proceeds. The individual transactions reported were:
- 257 shares at a weighted-average price of $247.22 — $63,536
- 232 shares at a weighted-average price of $248.11 — $57,562
- 697 shares at a weighted-average price of $249.53 — $173,924
- 3,405 shares at a weighted-average price of $251.62 — $856,752
- These were sales (not purchases or option exercises), which are often routine insider transactions and do not by themselves indicate company performance or insider sentiment.
Key Details
- Transaction date: June 10, 2026; Form 4 filed June 12, 2026 (appears timely).
- Aggregate proceeds: ≈ $1,151,774 for 4,591 shares.
- Shares owned after transaction: not specified in the provided filing excerpt.
- Footnotes: Each reported price is a weighted-average. Footnotes note that the shares were sold in multiple executions at price ranges (e.g., $246.63–$247.61; $247.94–$248.335; $249.34–$250.27; $250.91–$251.895). The reporting person will provide a breakdown of the number of shares sold at each price upon request.
- No indication in this filing of a 10b5‑1 plan, option exercise, gift, or tax-withholding disposition.
Context
- Sales by directors can be for many personal reasons (diversification, taxes, liquidity) and are common; they are less informative than insider purchases when assessing insider conviction.
- The filing shows straightforward open-market sales rather than derivative transactions or awards; no cashless exercise or immediate resale of exercised shares is involved.
Insider Transaction Report
Form 4
LAMATTINA JOHN L
Director
Transactions
- Sale
Common Stock
[F1]2026-06-10$247.22/sh−257$63,536→ 31,303 total - Sale
Common Stock
[F2]2026-06-10$248.11/sh−232$57,562→ 31,071 total - Sale
Common Stock
[F3]2026-06-10$249.53/sh−697$173,924→ 30,374 total - Sale
Common Stock
[F4]2026-06-10$251.62/sh−3,405$856,752→ 26,969 total
Footnotes (4)
- [F1]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $246.6300 to $247.6100. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F2]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $247.9400 to $248.3350. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $249.3400 to $250.2700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $250.9100 to $251.8950. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Signature
By: /s/ Andrew Reardon, Attorney-in-Fact For: John L. LaMattina|2026-06-12